Cogent Biosciences, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 192.41 million compared to USD 140.24 million a year ago. Basic loss per share from continuing operations was USD 2.42 compared to USD 2.39 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.02 USD | +0.17% | -10.28% | +2.38% |
Feb. 27 | North American Morning Briefing : Stock Futures -2- | DJ |
Feb. 26 | Citigroup Adjusts Price Target on Cogent Biosciences to $13 From $11, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.38% | 576M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- COGT Stock
- News Cogent Biosciences, Inc.
- Cogent Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023